Stage III Prostate Adenocarcinoma AJCC v7 Clinical Trial
Official title:
Phase I Feasibility Trial of Preoperative Adjuvant Stereotactic Body Radiotherapy for Patients at High Risk of Local Failure After Prostatectomy
Verified date | May 2022 |
Source | Jonsson Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I trial studies stereotactic body radiation therapy (SBRT) in treating patients with prostate cancer that is likely to come back or spread (high-risk) undergoing surgery. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Delivering radiotherapy before prostatectomy by SBRT is more convenient, conformal, and may spare normal tissues better than delivering radiotherapy after prostatectomy.
Status | Completed |
Enrollment | 11 |
Est. completion date | May 27, 2022 |
Est. primary completion date | May 9, 2020 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed primary non-metastatic adenocarcinoma of the prostate - Patient desires and is medically fit to undergo prostatectomy - Karnofsky performance status (KPS) >= 70 - Patients on androgen deprivation therapy (ADT) are allowed - For confirmation of high risk local failure status, patients will have any one of the following: - Computed tomography (CT) or magnetic resonance imaging (MRI) demonstrating seminal vesicle invasion (SVI) or extraprostatic extension (EPE) within 1 year of enrollment into the study - Pre-biopsy prostate-specific antigen (PSA) >= 20 - Gleason score 7-10 (Gleason 7 must be 4+3), presence of any Gleason 5 (even if a tertiary score) as determined at diagnostic biopsy - Gleason score 7 and > 50% of biopsy cores positive for prostate cancer - Clinical stage >= T3 (staging by imaging acceptable) - An image-guided biopsy (via Artemis Ultrasound with MRI co-registration) is encouraged but not required if not performed as standard of care biopsy Exclusion Criteria: - Distant metastases, based upon: - CT scan or MRI of the abdomen/pelvis or prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) within 120 days prior to registration and - Bone scan or PSMA PET/CT within 120 days prior to registration; if the bone scan is suspicious, a plain x-ray and/or MRI must be obtained to rule out metastasis prior to registration - Patient is unable or unwilling to sign consent - Patient is considered low-risk and would not have received adjuvant radiation therapy (RT) outside of this study |
Country | Name | City | State |
---|---|---|---|
United States | UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Jonsson Comprehensive Cancer Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Who Completed the Maximum Time Allowed on Study Without Severe Acute Surgical Complications | At 4 weeks post surgery | ||
Secondary | Number of Participants With Genitourinary Toxicities and Gastrointestinal Toxicities | Based on the Common Terminology Criteria for Adverse Events (CTCAE) v4. Grade refers to the severity of the adverse event. Indications are Grade 1 is Mild, Grade 2 is Moderate, Grade 3 is Severe or medically significant but not immediately life threatening. Grade 0 refers to absence of an adverse event (ae). | Up to 1 year | |
Secondary | Changes in Quality of Life (QOL) ,From Baseline to 12 Months, as Measured on the Expanded Prostate Cancer Index Composite (EPIC-26) Questionnaire Scoring. | The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) is composed of 26 items and measures health-related quality of life across 5 prostate cancer domains. Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing a better quality of life. | score from baseline to twelve months | |
Secondary | Changes in Quality of Life as Measured on the International Prostate Symptom Score (IPSS) Questionnaire. | The International Prostate Symptom Score is composed of seven questions and scored from 0 - 35, with higher scores indicating more severe symptoms. | Mean change in I-PSS score from baseline to 12 months. | |
Secondary | Correlative Biomarker Analyses Using Tissue and Serial Blood Samples | Tissue specimens of the primary tumor as well as blood draws before and after treatment will be used to conduct biomarker and molecular analyses relevant to understanding the biology of prostate SBRT | Baseline and to up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01787331 -
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
|
Phase 2 | |
Completed |
NCT02849990 -
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
|
Phase 2 | |
Active, not recruiting |
NCT01409200 -
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
|
Phase 2 | |
Active, not recruiting |
NCT03541850 -
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery
|
Phase 2 | |
Active, not recruiting |
NCT02099864 -
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
|
Phase 2 |